Perspective Therapeutics (NYSEAMERICAN:CATX) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Perspective Therapeutics (NYSEAMERICAN:CATX) issued its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03), FiscalAI reports. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million.

Perspective Therapeutics Stock Up 1.9%

Shares of CATX stock traded up $0.02 during mid-day trading on Monday, hitting $0.86. 2,931,788 shares of the stock traded hands, compared to its average volume of 2,354,917. Perspective Therapeutics has a twelve month low of $0.78 and a twelve month high of $6.16. The company’s 50-day simple moving average is $2.34 and its 200-day simple moving average is $3.49.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CATX shares. Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. William Blair initiated coverage on Perspective Therapeutics in a report on Friday, September 18th. They set an “outperform” rating on the stock. BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, September 15th. Finally, Bank of America reduced their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.